Related Experiment Video
Updated: Jun 26, 2025

04:46
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
1.5K
Automated online safety margin (GLIOVIS) for glioma surgery model
Marianne Mazevet1, Christian Oberli1, Sebastiano Marinelli1
1Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.
Frontiers in Oncology
|May 14, 2024
Summary
A new software, GLIOVIS, enhances glioblastoma surgery by analyzing 5-aminolevulinic acid (5-ALA) fluorescence. This tool creates intraoperative safety maps to better define tumor margins, improving surgical precision for brain cancer patients.
Area of Science:
- Neurosurgery
- Medical Imaging
- Oncology
Background:
- Glioblastoma is an aggressive brain tumor with poor prognosis.
- Current surgical resection relies on 5-aminolevulinic acid (5-ALA) fluorescence, but faces limitations like variability.
- Accurate identification of tumor infiltration margins is crucial for effective glioblastoma treatment.
Purpose of the Study:
- To introduce GLIOVIS, a novel software for analyzing 5-ALA-induced fluorescence images.
- To improve the recognition of tumor infiltration margins during glioblastoma surgery.
- To create an intraoperative safety map for enhanced surgical guidance.
Main Methods:
- Development of GLIOVIS software for quantitative analysis of Protoporphyrin IX fluorescence.
- Utilizing the Intraoperative Orbital Camera Olympus Orbeye (IOC) for image acquisition.
- Testing the software on gelatin-based brain models with varying fluorescence levels.
Main Results:
- GLIOVIS successfully processed images from brain models, generating fluorescence intensity maps.
- The software enabled the visualization of safety margins, aiding in tumor delineation.
- Qualitative digitalization of different fluorescence levels was achieved using this technique.
Conclusions:
- GLIOVIS demonstrates potential for image processing in 5-ALA-guided glioblastoma surgery.
- Validation on brain models shows promise for digitalizing fluorescence data.
- Further in vivo and clinical validation is required to establish GLIOVIS as a new standard of care.

